作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
-
[1] Leandro-García LJ, Leskelä S, Montero-Conde C, et al. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis[J]. Anal Biochem, 2009, 389:74-76. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0428c8212cecdced7a811bc61f8bd0a7 [2] He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes[J]. Trends Mol Med, 2011, 17:244-251. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=60521173&site=ehost-live [3] Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases[J]. Clin Pharmacol Ther, 2010, 88:354-359. doi: 10.1038/clpt.2009.216 [4] Meijerman I, Sanderson LM, Smits PH, et al. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6[J]. Drug Metab Rev, 2007, 39:45-60. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/03602530600952206 [5] 陈执中.人类基因组拷贝数变异与新药研究开发[C]//2007年全国生化与生物技术药物学术年会论文集.济南: 山东省科学技术协会, 2007. [6] Ramamoorthy A, Skaar TC. Gene copy number variations:it is important to determine which allele is affected[J]. Pharmacogenomics, 2011, 12:299-301. [7] Muller M. Pharmacogenomics and drug response[J]. Int J Clin Pharmacol Ther, 2003, 41:231-240. https://www.ncbi.nlm.nih.gov/pubmed/12816175 [8] Dalén P, Dahl M, Andersson K, et al. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes[J]. Br J Clin Pharmacol, 2000, 49:180-184. doi: 10.1046/j.1365-2125.2000.00120.x [9] Kiyotani K, Shimizu M, Kumai T, et al. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population[J]. Eur J Clin Pharmacol, 2010, 66:1065-1068. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=66bba3063c23ce88292e6b4f7fe11c3f [10] 朱志慧, 李树春, 徐斯凡.药物代谢酶CYP2D6基因多态性及表型的研究进展[J].国际遗传学杂志, 2009, 5:354-359. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-ycxfc200905009 [11] Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics:the contribution of allelic variations to the phenotype of drug response[J]. Mol Psychiatry, 2004, 9:442-473. [12] Dalén P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxy-lation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes[J]. Clin Pharmacol Ther, 1998, 63:444-452. http://www.onacademic.com/detail/journal_1000034131273710_e5c6.html [13] Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project[J]. Am J Psychiatry, 2010, 167:555-564. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=28b5d7a90fd771da3ab40371f7cbfd6a [14] 蔡卫民, 张宇馨.他莫昔芬的遗传药理学研究及其临床应用[J].世界临床药物, 2009, 11:698-701. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyy-hcy200911015 [15] Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen[J]. Breast Cancer Res Treat, 2004, 85:151-159. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=868dcdc7af2cd0ccc1639a60248c5996 [16] Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:implication for optimization of breast cancer treatment[J]. Clin Pharmacol Ther, 2006, 80:61-74. doi: 10.1016/j.clpt.2006.03.013 [17] Serrano D, Lazzeroni M, Zambon CF, et al. Efficacy of tamoxifen based on cytochrome P4502D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial[J]. Pharmacogenomics J, 2011, 11:100-107. https://core.ac.uk/display/53375882 [18] Schroth W, Hamann U, Fasching PA, et al. CYP2D6 poly-morphisms as predictors of outcome in breast cancer patients treated with tamoxifen:expanded polymorphism coverage improves risk stratification[J]. Clin Cancer Res, 2010, 16:4468-4477. [19] Prakash A, Markham A. Metoprolol:a review of its use in chronic heart failure[J]. Drugs, 2000, 60:647-678. https://pubmed.ncbi.nlm.nih.gov/11030472/ [20] Fux R, Mörike K, Pröhmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with meto-prolol:a prospective clinical study[J]. Clin Pharmacol Ther, 2005, 78:378-387. https://www.ncbi.nlm.nih.gov/pubmed/16198657 [21] Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P4502D6 on metoprolol pharmacokinetics and pharmacodynamics[J]. Clin Pharmacol Ther, 2004, 76:302-312. http://www.tandfonline.com/servlet/linkout?suffix=CIT0110&dbid=8&doi=10.1185%2F03007995.2011.562884&key=15470329 [22] Goryachkina K, Burbello A, Boldueva S, et al. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction[J]. Eur J Clin Pharmacol, 2008, 64:1163-1173. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1d3f5d986c47308801e2a6b5495a6b02 [23] Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication[J]. Pharmaco-genomics J, 2007, 7:257-265. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=c5b82ba4f164108015129232dffceb07 [24] Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death[J]. N Engl J Med, 2009, 361:827-828. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1a8c0df2023cced519df3e7dfebeb599 [25] Madadi P, Ciszkowski C, Gaedigk A, et al. Genetic transmission of cytochrome P4502D6(CYP2D6) ultrarapid metabolism:implications for breastfeeding women taking co-deine[J]. Curr Drug Saf, 2011, 6:36-39. http://www.ncbi.nlm.nih.gov/pubmed/21241245 [26] 李成涛, 赵书, 民李莉.拷贝数变异研究新进展[J].中国司法鉴定, 2009, 4:36-38. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsfjd200904008 [27] Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR[J]. Hum Mutat, 2003, 22:476-485. doi: 10.1002/humu.10280 [28] Endrizzi K, Fischer J, Klein K, et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction[J]. Anal Biochem, 2002, 300:121-131. http://www.europepmc.org/abstract/MED/11779102 [29] 吴志俊, 金玮.拷贝数变异:基因组多样性的新形式[J].遗传, 2009, 31:339-347. -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 253
- HTML全文浏览量: 75
- PDF下载量: 19
- 被引次数: 0
